down arrow

Aquestive Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03843E1047
USD
6.44
0.51 (8.6%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
MediWound Ltd.
Pyxis Oncology, Inc.
Aquestive Therapeutics, Inc.
DiaMedica Therapeutics, Inc.
Abeona Therapeutics, Inc.
GlycoMimetics, Inc.
Milestone Pharmaceuticals, Inc.
Achieve Life Sciences, Inc.
Atossa Therapeutics, Inc.
MediciNova, Inc.
Relmada Therapeutics, Inc.
Why is Aquestive Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Net Sales has grown by an annual rate of -5.73% and Operating profit at -14.03% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.40
2
The company has declared negative results for the last 3 consecutive quarters
  • OPERATING CASH FLOW(Y) Lowest at USD -49.68 MM
  • NET SALES(Q) At USD 10 MM has Fallen at -50.23%
  • PRE-TAX PROFIT(Q) At USD -13.55 MM has Fallen at -393.55%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 26.61%, its profits have fallen by -95.5%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aquestive Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aquestive Therapeutics, Inc.
46.7%
1.59
75.96%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-5.73%
EBIT Growth (5y)
-14.03%
EBIT to Interest (avg)
-2.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
-1.00
Tax Ratio
0.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.87%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-5.80
EV to EBIT
-9.83
EV to EBITDA
-9.99
EV to Capital Employed
-41.09
EV to Sales
7.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

5What is working for the Company
NET PROFIT(HY)

Higher at USD -36.48 MM

DEBT-EQUITY RATIO (HY)

Lowest at -90.54 %

-31What is not working for the Company
OPERATING CASH FLOW(Y)

Lowest at USD -49.68 MM

NET SALES(Q)

At USD 10 MM has Fallen at -50.23%

PRE-TAX PROFIT(Q)

At USD -13.55 MM has Fallen at -393.55%

NET PROFIT(Q)

At USD -13.55 MM has Fallen at -393.55%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.28 times

RAW MATERIAL COST(Y)

Grown by 30.18% (YoY

Here's what is working for Aquestive Therapeutics, Inc.
Debt-Equity Ratio
Lowest at -90.54 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Aquestive Therapeutics, Inc.
Net Sales
At USD 10 MM has Fallen at -50.23%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -13.55 MM has Fallen at -393.55%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -13.55 MM has Fallen at -393.55%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -49.68 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Inventory Turnover Ratio
Lowest at 2.28 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost
Grown by 30.18% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."